125 related articles for article (PubMed ID: 36642656)
1. Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors.
Zhu C; Sandilos G; Williamson J; Emery R; Platoff R; Joneja U; Acharya NK; Lin A; Badach J; Zilberman B; Madzo J; Jelinek J; Zhang P; Hong YK
Surgery; 2023 Apr; 173(4):1045-1051. PubMed ID: 36642656
[TBL] [Abstract][Full Text] [Related]
2. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
[TBL] [Abstract][Full Text] [Related]
3. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
[TBL] [Abstract][Full Text] [Related]
4. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
Monazzam A; Li SC; Wargelius H; Razmara M; Bajic D; Mi J; Bergquist J; Crona J; Skogseid B
Sci Rep; 2020 Sep; 10(1):14572. PubMed ID: 32884006
[TBL] [Abstract][Full Text] [Related]
6. MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183.
Zhang YY; Feng HM
Cell Physiol Biochem; 2017; 44(1):345-356. PubMed ID: 29132136
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors.
Larsson C
Neuroendocrinology; 2013; 97(1):19-25. PubMed ID: 22456267
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.
Gailhouste L; Liew LC; Hatada I; Nakagama H; Ochiya T
Cell Death Dis; 2018 May; 9(5):468. PubMed ID: 29700299
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line.
Lou X; Ye Z; Xu X; Jiang M; Lu R; Jing D; Zhang W; Gao H; Wang F; Zhang Y; Chen X; Qin Y; Zhuo Q; Yu X; Ji S
Hum Cell; 2022 Jul; 35(4):1248-1261. PubMed ID: 35394261
[TBL] [Abstract][Full Text] [Related]
12. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study.
Fotouhi O; Adel Fahmideh M; Kjellman M; Sulaiman L; Höög A; Zedenius J; Hashemi J; Larsson C
Epigenetics; 2014 Jul; 9(7):987-97. PubMed ID: 24762809
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A
Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592
[TBL] [Abstract][Full Text] [Related]
14. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 May; 126(5):326-335. PubMed ID: 29451738
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors).
Choi IS; Estecio MR; Nagano Y; Kim DH; White JA; Yao JC; Issa JP; Rashid A
Mod Pathol; 2007 Jul; 20(7):802-10. PubMed ID: 17483816
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis.
Liu L; Broaddus RR; Yao JC; Xie S; White JA; Wu TT; Hamilton SR; Rashid A
Mod Pathol; 2005 Dec; 18(12):1632-40. PubMed ID: 16258509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
